| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
165,859 |
136,205 |
$7.18M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
49,855 |
42,596 |
$1.41M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
19,214 |
15,330 |
$971K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
31,449 |
26,333 |
$903K |
| 99490 |
Ccm add 20min |
34,048 |
33,257 |
$653K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14,567 |
12,064 |
$641K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
43,854 |
38,217 |
$548K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
5,934 |
5,800 |
$485K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,755 |
6,453 |
$388K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,137 |
5,874 |
$358K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
19,898 |
15,871 |
$323K |
| 99442 |
|
11,063 |
9,726 |
$304K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
3,523 |
3,412 |
$267K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
8,097 |
6,775 |
$208K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,330 |
1,201 |
$144K |
| 90674 |
|
6,219 |
6,036 |
$112K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
25,702 |
20,566 |
$109K |
| 92546 |
|
2,421 |
2,161 |
$97K |
| 92540 |
|
2,367 |
2,216 |
$90K |
| 80061 |
Lipid panel |
13,760 |
13,298 |
$82K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
8,365 |
7,774 |
$79K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,537 |
2,318 |
$79K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
7,072 |
6,857 |
$76K |
| 94729 |
|
2,478 |
2,423 |
$68K |
| 94060 |
|
2,471 |
2,424 |
$66K |
| 99408 |
|
8,096 |
7,924 |
$66K |
| 80050 |
General health panel |
3,682 |
3,485 |
$63K |
| 99401 |
|
2,521 |
2,437 |
$60K |
| 93000 |
|
6,238 |
6,058 |
$58K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
1,602 |
1,490 |
$56K |
| 93923 |
|
1,070 |
1,046 |
$54K |
| 80053 |
Comprehensive metabolic panel |
14,903 |
14,326 |
$54K |
| 80305 |
|
8,601 |
6,421 |
$53K |
| 94727 |
|
2,482 |
2,426 |
$52K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
905 |
895 |
$47K |
| 82607 |
|
8,000 |
7,554 |
$43K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,721 |
13,247 |
$43K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,388 |
6,111 |
$42K |
| 82948 |
|
36,870 |
28,363 |
$42K |
| 95886 |
|
498 |
456 |
$39K |
| 36415 |
Collection of venous blood by venipuncture |
30,180 |
26,255 |
$38K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
24,088 |
20,732 |
$38K |
| 92576 |
|
1,965 |
1,788 |
$34K |
| 93922 |
|
1,003 |
966 |
$34K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
2,188 |
415 |
$33K |
| 82746 |
|
6,486 |
6,104 |
$32K |
| G0445 |
High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes |
1,781 |
1,770 |
$28K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,734 |
1,405 |
$26K |
| 95912 |
|
233 |
213 |
$24K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
28,628 |
24,900 |
$23K |
| 90688 |
|
1,896 |
1,806 |
$23K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
237 |
172 |
$21K |
| 95911 |
|
212 |
210 |
$19K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
354 |
331 |
$18K |
| 99343 |
|
68 |
67 |
$16K |
| 81003 |
|
15,316 |
14,713 |
$15K |
| 92250 |
|
817 |
757 |
$15K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
521 |
515 |
$15K |
| 99397 |
|
337 |
320 |
$14K |
| 84153 |
|
2,069 |
1,964 |
$13K |
| 99385 |
|
180 |
174 |
$13K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
9,344 |
7,372 |
$11K |
| 96160 |
|
6,135 |
6,018 |
$11K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
248 |
243 |
$10K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,272 |
2,237 |
$10K |
| 11721 |
|
855 |
743 |
$9K |
| 92547 |
|
2,362 |
2,212 |
$9K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
3,100 |
2,889 |
$7K |
| 83735 |
|
2,767 |
2,671 |
$7K |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
1,171 |
972 |
$6K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
137 |
137 |
$6K |
| 86769 |
|
172 |
160 |
$5K |
| 83540 |
|
2,346 |
2,184 |
$5K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
507 |
491 |
$5K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
655 |
630 |
$5K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
21 |
14 |
$4K |
| 84403 |
|
439 |
415 |
$4K |
| 99349 |
|
409 |
385 |
$3K |
| H0006 |
Alcohol and/or drug services; case management |
108 |
56 |
$3K |
| 84550 |
|
1,999 |
1,916 |
$3K |
| 11056 |
|
263 |
235 |
$3K |
| 82962 |
|
4,250 |
3,243 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
54 |
49 |
$3K |
| 82043 |
|
3,726 |
3,466 |
$3K |
| 82570 |
|
2,990 |
2,839 |
$3K |
| S9470 |
Nutritional counseling, dietitian visit |
190 |
173 |
$3K |
| G0008 |
Administration of influenza virus vaccine |
829 |
783 |
$2K |
| 99386 |
|
27 |
27 |
$2K |
| 76872 |
|
45 |
44 |
$2K |
| 84156 |
|
2,081 |
2,022 |
$2K |
| 93978 |
|
84 |
80 |
$2K |
| 86328 |
|
56 |
55 |
$2K |
| 96138 |
|
420 |
342 |
$2K |
| 96132 |
|
174 |
151 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
105 |
94 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
105 |
94 |
$2K |
| 86580 |
|
252 |
218 |
$1K |
| 81002 |
|
1,621 |
1,570 |
$1K |
| 93880 |
|
61 |
44 |
$1K |
| 95923 |
|
32 |
31 |
$1K |
| 92228 |
|
175 |
151 |
$1K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
134 |
133 |
$987.23 |
| 90736 |
|
15 |
12 |
$952.03 |
| 95921 |
|
32 |
31 |
$828.81 |
| 95885 |
|
12 |
12 |
$690.79 |
| 86592 |
|
560 |
422 |
$648.70 |
| 99000 |
|
585 |
558 |
$484.76 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
742 |
673 |
$426.64 |
| 76770 |
|
13 |
13 |
$356.56 |
| 76857 |
|
20 |
19 |
$339.46 |
| 82270 |
|
292 |
225 |
$324.48 |
| 99307 |
|
70 |
14 |
$318.48 |
| 99348 |
|
16 |
16 |
$264.85 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
22 |
21 |
$237.62 |
| 90756 |
|
14 |
14 |
$210.18 |
| 90653 |
|
13 |
12 |
$171.96 |
| 90656 |
|
12 |
12 |
$168.65 |
| 99072 |
|
4,500 |
3,840 |
$141.00 |
| 99406 |
|
13 |
12 |
$132.83 |
| 99453 |
|
12 |
12 |
$132.73 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$124.20 |
| J1940 |
Injection, furosemide, up to 20 mg |
118 |
105 |
$97.24 |
| 3080F |
|
7,774 |
6,854 |
$49.00 |
| 3008F |
|
9,559 |
9,046 |
$40.00 |
| 3078F |
|
39,167 |
32,058 |
$22.00 |
| 3074F |
|
36,021 |
29,744 |
$18.00 |
| 3077F |
|
15,891 |
13,933 |
$12.00 |
| 92700 |
|
21 |
17 |
$10.00 |
| 3079F |
|
26,036 |
22,576 |
$10.00 |
| 3075F |
|
21,189 |
18,496 |
$9.00 |
| 2022F |
|
127 |
125 |
$7.00 |
| 1170F |
|
1,566 |
1,406 |
$6.00 |
| 1160F |
|
1,899 |
1,725 |
$2.00 |
| 3061F |
|
1,058 |
1,035 |
$1.00 |
| 1159F |
|
1,529 |
1,381 |
$1.00 |
| 1126F |
|
285 |
244 |
$0.01 |
| 1125F |
|
1,670 |
1,498 |
$0.00 |
| 3060F |
|
30 |
30 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
7,902 |
7,404 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
423 |
376 |
$0.00 |
| 1157F |
|
1,224 |
1,129 |
$0.00 |
| 2000F |
|
2,938 |
2,617 |
$0.00 |
| 3014F |
|
818 |
758 |
$0.00 |
| 3072F |
|
218 |
198 |
$0.00 |
| 80069 |
|
835 |
815 |
$0.00 |
| 3044F |
|
1,523 |
1,447 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
13 |
13 |
$0.00 |
| 81528 |
Oncology (colorectal) screening, quantitative real-time target and signal amplification |
41 |
41 |
$0.00 |
| 2023F |
|
16 |
15 |
$0.00 |
| 3052F |
|
24 |
24 |
$0.00 |
| 81005 |
|
41 |
41 |
$0.00 |
| 3048F |
|
12 |
12 |
$0.00 |
| 1158F |
|
637 |
585 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
6,804 |
6,291 |
$0.00 |
| 3051F |
|
292 |
284 |
$0.00 |
| 3046F |
|
119 |
115 |
$0.00 |
| 3288F |
|
2,052 |
1,821 |
$0.00 |
| 3015F |
|
162 |
145 |
$0.00 |
| 77061 |
|
87 |
75 |
$0.00 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
14 |
14 |
$0.00 |
| 82565 |
|
51 |
51 |
$0.00 |
| 1100F |
|
169 |
151 |
$0.00 |